Roots Analysis has done a detailed study on Antibody Discovery:
Services and Platforms Market (3rd Edition), 2020-2030, covering key aspects of the industry’s evolution and
identifying potential future growth opportunities.
To order this 450+ page report, which features 120+
figures and 140+ tables, please visit this link
Key
Market Insights
§
§
§
§
§
§
§
§
For more information, please visit https://www.rootsanalysis.com/reports/view_document/antibody-discovery-services-and-platforms/213.html
Table of Contents
1. PREFACE
1.1.
Scope of the Report
1.2.
Research Methodology
1.3.
Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1.
Chapter Overview
3.2.
Structure of Antibodies
3.3.
History of Development
3.4.
Antibody Isotypes
3.5.
Mechanism of Action of Antibodies
3.6.
Classification of Antibodies
3.6.1.
Monoclonal Antibodies
3.6.2.
Polyclonal Antibodies
3.6.3.
Bispecific Antibodies
3.7.
Applications of Antibodies
4. ANTIBODY DISCOVERY PROCESS AND METHODS
4.1.
Chapter Overview
4.2.
Antibody Discovery Process
4.2.1.
Target Selection and Validation
4.2.2.
Hit Generation
4.2.3. Lead Selection
4.2.4. Lead Optimization
4.2.4.1. Humanization
4.2.4.2. Affinity Maturation
4.2.4.3. Fc Engineering
4.2.5. Lead Characterization
4.2.6. Candidate Selection
4.3. Antibody Discovery Methods
4.3.1. Hybridoma Method
4.3.2. In vitro Display Method
4.3.2.1. Phage Display
4.3.2.2. Yeast Display
4.3.2.3. Ribosomal Display
4.3.3. Transgenic Animal-Based Method
4.3.4. Single B Cell-Based Method
4.3.5. Advantages and Disadvantages of Existing
Antibody Discovery Techniques
4.4. Evolution of Monoclonal Antibodies
4.4.1. Fully Human Monoclonal Antibodies
5. ANTIBODY DISCOVERY SERVICE PROVIDERS:
CURRENT MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Antibody Discovery Service Providers:
List of Industry Players
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Type of Service Offered
5.2.5. Analysis by Type of Antibody Discovery
Method
5.2.6. Grid Representation: Analysis by Type of
Service Offered, Type of Antibody Discovery Method and Company Size
5.2.7. Analysis by Animal Model Used
5.2.8. Analysis by Type of Antibody Discovered
5.2.9. Analysis by Type of Antibody Discovery
Method and Type of Antibody Discovered
5.2.10. Analysis by Purpose of Antibody Discovery
5.2.11. Analysis by Type of Antibody Discovery Method
and Purpose of Antibody Discovery
6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Methodology
6.3. Key Parameters
6.4. Competitiveness Analysis: Antibody
Discovery Service Providers
6.4.1. Antibody Discovery Service Providers based
in North America
6.4.2. Antibody Discovery Service Providers based
in Europe
6.4.3. Antibody Discovery Service Providers based
in Asia Pacific
7. COMPANY PROFILES: ANTIBODY DISCOVERY
SERVICE PROVIDERS
7.1. Chapter Overview
7.2. Antibody Discovery Service Providers in
North America
7.2.1. Abwiz Bio
7.2.1.1. Company Overview
7.2.1.2. Antibody Discovery Services
7.2.1.3. Recent Developments and Future Outlook
7.2.2. Aragen Bioscience (A GVK BIO Company)
7.2.2.1. Company Overview
7.2.2.2. Antibody Discovery Services
7.2.2.3. Recent Developments and Future Outlook
7.2.3. Distributed Bio
7.2.3.1. Company Overview
7.2.3.2. Antibody Discovery Services
7.2.3.3. Recent Developments and Future Outlook
7.2.4. Integral Molecular
7.2.4.1. Company Overview
7.2.4.2. Antibody Discovery Services
7.2.4.3. Recent Developments and Future Outlook
7.2.5. LakePharma
7.2.5.1. Company Overview
7.2.5.2. Antibody Discovery Services
7.2.5.3. Recent Developments and Future Outlook
7.3. Antibody Discovery Service Providers in
Europe
7.3.1. Abzena
7.3.1.1. Company Overview
7.3.1.2. Financial Information
7.3.1.3. Antibody Discovery Services
7.3.1.4. Recent Developments and Future Outlook
7.3.2. ImmunoPrecise Antibodies
7.3.2.1. Company Overview
7.3.2.2. Financial Information
7.3.2.3. Antibody Discovery Services
7.3.2.4. Recent Developments and Future Outlook
7.3.3. PX'Therapeutics (Subsidiary of Aguettant
Pharmaceutical Group)
7.3.3.1. Company Overview
7.3.3.2. Antibody Discovery Services
7.3.3.3. Recent Developments and Future Outlook
7.4. Antibody Discovery Service Providers in
Asia-Pacific
7.4.1. ChemPartner
7.4.1.1. Company Overview
7.4.1.2. Antibody Discovery Services
7.4.1.3. Recent Developments and Future Outlook
7.4.2. Viva Biotech
7.4.2.1. Company Overview
7.4.2.2. Financial Information
7.4.2.3. Antibody Discovery Services
7.4.2.4. Recent Developments and Future Outlook
7.4.3. WuXi Biologics
7.4.3.1. Company Overview
7.4.3.2. Financial Information
7.4.3.3. Antibody Discovery Services
7.4.3.4. Recent Developments and Future Outlook
8. ANTIBODY DISCOVERY TECHNOLOGIES:
CURRENT MARKET LANDSCAPE
8.1. Chapter Overview
8.2. Antibody Discovery Platform Providers:
List of Industry Players
8.2.1. Analysis by Year of Establishment
8.2.2. Analysis by Company Size
8.2.3. Analysis by Location of Headquarters
8.2.4. Analysis by Type of Antibody Discovered
8.3. Antibody Discovery: List of Technologies
and Platforms
8.3.1. Analysis by Type of Antibody Discovery
Method
8.3.2. Analysis by Type of Antibody Discovery
Method and Location of Headquarters
8.3.3. Analysis by Animal Model Used
8.3.4. Analysis by Patent Availability
9. TECHNOLOGY COMPETITIVENESS ANALYSIS
9.1. Chapter Overview
9.2. Methodology
9.3. Key Parameters
9.4. Technology Competitiveness Analysis:
Antibody Discovery Platforms
9.4.1. Competitiveness Analysis: Library Based
Antibody Discovery Platforms
9.4.2. Competitiveness Analysis: Single Cell Based
Antibody Discovery Platforms
9.4.3. Competitiveness Analysis: Transgenic Animal
Based Antibody Discovery Platforms
9.4.4. Competitiveness Analysis: Other Antibody
Discovery Platforms
10. COMPANY PROFILES: ANTIBODY DISCOVERY
PLATFORM PROVIDERS
10.1. Chapter Overview
10.2. ImmunoPrecise Antibodies
10.2.1. Company Overview
10.2.2. Financial Information
10.2.3. Portfolio of Antibody Discovery Platforms
10.2.3.1.
Abthena™
10.2.3.2.
B cell Select™
10.2.3.3.
DeepDisplay™
10.2.3.4.
ModiFuse™
10.2.3.5.
ModiPhage™
10.2.3.6.
ModiSelect™
10.2.3.7.
ModiTune™
10.2.4. Recent
Developments and Future Outlook
10.3. Harbour BioMed
10.3.1. Company Overview
10.3.2. Portfolio of Antibody Discovery Platforms
10.3.2.1.
H2L2 Platform
10.3.2.2.
HCAb Platform
10.3.3. Recent
Developments and Future Outlook
10.4. Kymab
10.4.1. Company Overview
10.4.2. Portfolio of Antibody Discovery Platforms
10.4.2.1.
Kymouse™
10.4.2.2.
IntelliSelect®
10.4.3. Recent
Developments and Future Outlook
10.5. Ligand Pharmaceuticals
10.5.1. Company Overview
10.5.2. Financial Information
10.5.3. Portfolio of Antibody Discovery Platforms
10.5.3.1.
OmniAb®
10.5.3.1.1.
OmniChicken®
10.5.3.1.2.
OmniClic™
10.5.3.1.3.
OmniFlic®
10.5.3.1.4.
OmniMouse®
10.5.3.1.5.
OmniRat®
10.5.4. Recent Developments and Future Outlook
10.6. MorphoSys
10.6.1. Company Overview
10.6.2. Financial Information
10.6.3. Portfolio of Antibody Discovery Platforms
10.6.3.1.
arYla® Technology
10.6.3.2.
HuCAL® Technology
10.6.3.3.
Ylanthia® Technology
10.6.4. Recent Developments and Future Outlook
11. REGIONAL CAPABILITY ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions and Methodology
11.3. Regional Capability Analysis: Antibody
Discovery Service Providers
11.3.1. Regional Capability Analysis: Distribution of
Antibody Discovery Service Providers based in North America
11.3.2. Regional Capability Analysis: Distribution of
Antibody Discovery Service Providers based in Europe
11.3.3. Regional Capability Analysis: Distribution of
Antibody Discovery Service Providers based in Asia-Pacific
11.4. Regional Capability Analysis: Antibody
Discovery Platform Providers
11.4.1. Regional Capability Analysis: Distribution of
Antibody Discovery Platform Providers based in North America
11.4.2. Regional Capability Analysis: Distribution of
Antibody Discovery Platform Providers based in Europe
11.4.3. Regional Capability Analysis: Distribution of
Antibody Discovery Platform Providers based in Asia-Pacific
11.5. Concluding Remarks
12. PARTNERSHIPS AND COLLABORATIONS
12.1. Chapter Overview
12.2. Partnership Models
12.3. List of Partnerships and Collaborations
12.3.1. Analysis by Year of Partnership
12.3.2. Analysis by Type of Partnership
12.3.3. Analysis by the Type of Company (Service / Platform
Providers)
12.3.4. Analysis by Type of Antibody Discovered
12.3.5. Analysis by Year of Partnership and Type of
Partner
12.3.6. Analysis by Type of Partnership and Type of
Partner
12.3.7. Most Active Players: Analysis by Number of
Partnerships
12.3.8. Most Popular Technologies: Analysis by Number
of Partnerships
12.3.9. Regional Analysis
12.3.9.1.
Intercontinental and Intracontinental Agreements
13. FUNDING AND INVESTMENT ANALYSIS
13.1. Chapter Overview
13.2. Types of Funding
13.3. Antibody Discovery Service and Platform
Providers: Funding and Investment Analysis
13.3.1. Analysis by Number of Instances
13.3.2. Analysis by Amount Invested
13.3.3. Analysis by Type of Funding
13.3.4. Most Active Players: Analysis by Amount
Invested
13.3.5. Most Active Investors: Analysis by Number of
Funding Instances
13.3.6. Regional Analysis by Amount Invested
13.4. Concluding Remarks
14. ANTIBODY DISCOVERY SERVICES: MARKET
FORECAST
14.1. Chapter Overview
14.2. Forecast Methodology
14.3. Global Antibody Discovery Services Market,
2020-2030
14.4. Global Antibody Discovery Services Market:
Distribution by Steps Involved in Antibody Discovery Process, 2020-2030
14.4.1. Antibody Discovery Services Market for
Antigen Designing, 2020-2030
14.4.2. Antibody Discovery Services Market for Hit
Generation, 2020-2030
14.4.3. Antibody Discovery Services Market for Lead
Selection, 2020-2030
14.4.4. Antibody Discovery Services Market for Lead
Optimization, 2020-2030
14.4.5. Antibody Discovery Services Market for Lead
Characterization, 2020-2030
14.5. Global Antibody Discovery Services Market:
Distribution by Antibody Discovery Method, 2020-2030
14.5.1. Antibody Discovery Services Market for Phage
Display, 2020-2030
14.5.2. Antibody Discovery Services Market for Yeast
Display, 2020-2030
14.5.3. Antibody Discovery Services Market for
Hybridoma Method, 2020-2030
14.5.4. Antibody Discovery Services Market for
Transgenic Animal Based Method, 2020-2030
14.5.5. Antibody Discovery Services Market for Single
Cell Based Method, 2020-2030
14.5.6. Antibody Discovery Services Market for Other
Methods, 2020-2030
14.6. Global Antibody Discovery Services Market:
Distribution by Nature of Antibody Generated, 2020-2030
14.6.1. Antibody Discovery Services Market for
Humanized Antibodies, 2020-2030
14.6.2. Antibody Discovery Services Market for Human
Antibodies, 2020-2030
14.6.3. Antibody Discovery Services Market for
Chimeric Antibodies, 2020-2030
14.6.4. Antibody Discovery Services Market for Murine
Antibodies, 2020-2030
14.7. Global Antibody Discovery Services Market:
Distribution by Region, 2020-2030
14.7.1. Antibody Discovery Services Market in North
America, 2020-2030
14.7.2. Antibody Discovery Services Market in Europe,
2020-2030
14.7.3. Antibody Discovery Services Market in
Asia-Pacific and Rest of the World, 2020-2030
14.7.4. Antibody Discovery Services: Market Attractiveness
Analysis by Region
15. ANTIBODY DISCOVERY TECHNOLOGIES: MARKET
FORECAST
15.1. Chapter Overview
15.2. Key Assumptions
15.3. Forecast Methodology
15.4. Global Antibody Discovery Platforms
Market, 2020-2030
15.5. Global Antibody Discovery Platforms
Market: Distribution by Region, 2020-2030
15.5.1. Antibody Discovery Platforms Market in North
America, 2020-2030
15.5.2. Antibody Discovery Platforms Market in
Europe, 2020-2030
15.5.3. Antibody Discovery Platforms Market in
Asia-Pacific, 2020-2030
16. CASE IN POINT: DRUG DISCOVERY PROCESSES
OF TOP SELLING ANTIBODIES
16.1. Chapter Overview
16.2. Humira® (Adalimumab)
16.2.1. Drug Overview
16.2.2. Discovery Process and Method
16.2.3. Historical Sales
16.3. Keytruda® (Pembrolizumab)
16.3.1. Drug Overview
16.3.2. Discovery Process and Method
16.3.3. Historical Sales
16.4. Herceptin® (Trastuzumab)
16.4.1. Drug Overview
16.4.2. Discovery Process and Method
16.4.3. Historical Sales
16.5. Avastin® (Bevacizumab)
16.5.1. Drug Overview
16.5.2. Discovery Process and Method
16.5.3. Historical Sales
16.6. Rituxan® (Rituximab)
16.6.1. Drug Overview
16.6.2. Discovery Process and Method
16.6.3. Historical Sales
17. CASE STUDY: ANTIBODY HUMANIZATION AND
AFFINITY MATURATION
17.1. Importance of Antibody Humanization and
Affinity Maturation
17.2. Antibody Humanization and Affinity
Maturation Service and Platform Providers: Market Landscape
17.3. Antibody Humanization: Publication
Analysis
17.3.1. Publication Analysis: Year-Wise Trend
17.3.2. Publication Analysis: Key Journals
17.3.3. Publication Analysis: Distribution by Animal
Model Used
17.3.4. Publication Analysis: Distribution by Method
Used for Humanization
17.4. Antibody Humanization Service and Platform
Providers: SWOT Analysis
18. FUTURE GROWTH OPPORTUNITIES IN ANTIBODY
DISCOVERY
18.1. Chapter Overview
18.2. Anticipated Shift from Monoclonal
Antibodies to Other Novel Formats
18.3. Technological Advancements to Overhaul
Conventional Antibody Discovery Processes
18.4. Transition to CADD-based Approaches to
Help Achieve Better Operational Efficiencies
18.5. Rising Demand for Antibody-based Treatment
Options across Non-Oncology Indications
18.6. Growing Market Opportunities in the
Asia-Pacific Region
18.7. Expected Increase in Number of
Collaborations and Licensing Activity
18.8.
Concluding Remarks
19. EXECUTIVE INSIGHTS
19.1. Chapter Overview
19.2. Abveris Antibody
19.2.1. Company Snapshot
19.2.2. Tracey Mullen, Chief Executive Officer (Q2
2020)
19.3. Nidus Biosciences
19.3.1. Company Snapshot
19.3.2. Lisa Delouise, Founder and Chief Technology
Officer (Q1 2020)
19.4. AvantGen
19.4.1. Company Snapshot
19.4.2. Mark Kubik, Chief Business Officer (Q1 2020)
19.5. Single Cell Technology
19.5.1. Company Snapshot
19.5.2. Chun-Nan Chen, Chief Executive Officer and
Chief Scientific Officer (Q2 2018)
19.6. Distributed Bio
19.6.1. Company Snapshot
19.6.2. Giles Day, Co-Founder and Chief Executive
Officer (Q2 2018)
19.7. AbCellera
19.7.1. Company Snapshot
19.7.2. Kevin Heyries, Co-Founder and Lead of
Business Development Strategy (Q2 2018)
19.8. AbGenics Life Sciences
19.8.1. Company Snapshot
19.8.2. Sanjiban K Banerjee, Director (Q2 2018)
19.9. CDI Laboratories
19.9.1. Company Snapshot
19.9.2. Ignacio Pino, Chief Executive Officer and
President (Q2 2017)
19.10. AP Biosciences
19.10.1.
Company Snapshot
19.10.2.
Jeng Her, Chief Executive Officer (Q2 2017)
19.11. YUMAB
19.11.1.
Company Snapshot
19.11.2.
Thomas Schirrmann, Chief Executive Officer and General Manager (Q2 2017)
19.12. Antibody Solutions
19.12.1.
Company Snapshot
19.12.2.
Debra Valsamis, Business Development Associate (Q2 2017)
19.13. Ligand Pharmaceuticals
19.13.1.
Company Snapshot
19.13.2.
Christel Iffland, Vice President (Q2 2017)
19.14. LakePharma
19.14.1.
Company Snapshot
19.14.2.
Aaron Sato, Chief Scientific Officer (Q2 2017)
20. CONCLUDING REMARKS
20.1. Chapter Overview
20.2. Key Takeaways
21. APPENDIX 1: TABULATED DATA
22. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Gaurav Chaudhary
+1 (415) 800 3415